Las Condes

81 / 164

211
REFERENCIAS BIBLIOGRáFICAS
1. Turner, RC; Holman RR, Matthews DR, Bassett PA, Coster R,
Stratton IM et als. Hypertension in diabetes study (HDS).1.
Prevalence of hypertension in newly presenting type-2
diabetic-patients and the association with risk-factors for
cardiovascular and diabetic complications. J Hypertens
1993;11: 309 – 317).
2. Norman Kaplan and Ronald G Victor. Clinical Hypertension,
XI th Edition Wolters Kluwer, pg 287 – 291, Philadelphia PA,
2015.
3. Epstein M, Sowers JR. Diabetes Mellitus and Hypertension.
Hypertension 1992; 19:403-18.
4. Wijkman M, Lanne T, Engvall J, Lindstrom T, Ostgren CJ, N y
Strom FH. Masked nocturnal hypertension: a novel marker of
risk in type 2 diabetes Diabetologia 2009; 52:1258–1264.
5. The Task Force for the management of arterial hypertension
of the European Society of Hypertension (ESH) and of
the European Society of Cardiology (ESC) 2013 ESH/ESC
Guidelines for the management of arterial hypertension” J
Hypertension 2013; 31: 1320 – 1321.
6. Poblete H, Sociedad Chilena de Nefrología, Registro de
diálisis. XXXIV Cuenta de Hemodiálisis Crónica en Chile,
al 31-8-2014.
comparte/biblioteca/cuenta-hemodialisis/finish/6-cuentas-
hemodialisis/820-cuenta-final-xxxiv-hdc-2014).
7. UK Prospective Diabetes Study Group. Tight blood pressure
control and risk of macrovascular and microvascular
complications in type 2 diabetes: UKPDS 38. BMJ
1998;317:703–13.
8. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D,
Julius s, et al for the HOT Study Group. Effects of intensive
blood-pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension
Optimal Treatment (HOT) randomised trial. Lancet 1998;
351: 1755–62.
9. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive
blood pressure control in normotensive type 2 diabetic
patients on albuminuria, retinopathy and strokes. Kidney
International, 2002; 61:1086–97.
10. Rennke HG, Denker BMRenal Pathophysiology, The Essentials,
2nd Edition, Philadelphia, Lippincott Williams & Wilkins,
2007, pgs 267-290.
11. T. H. Hostetter, J. L. Olson, H. G. Rennke, M. A. Venkatachalam,
and B. M. Brenner. Hyperfiltration in remnant nephrons: a
potentially adverse response to renal ablation. Am. J. Physiol.
1981; 241: F85-F93.
12. Anderson S, Rennke HG, García DL et al Short and long term
effects of antihypertensive theraphy in the diabetic rats
Kidney International 1989; 36: 526.
13. Benner B.M. Nephron adaptation to renal injury or ablation.
Am. J. Physiol. 1985; 249 (Renal Fluid Electrolyte Physiol.
18): F324-F337.
14. Zatz R, Meyer T.W., Rennke HG, Brenner BM: Predominance
of hemodynamic rather than metabolic factors in the
pathogenesis of diabetic glomerulopathy. Proc. Natl. Acad.
Sci. USA 1985; 82: 5963-5967.
15. Mahmoud Barazi1, Harneet Kaur and Sharma Prabhakar
Diabetic Glomerulopathy en Sharma S. Prabhakar (editor) “An
Update on Glomerulopathies –Clinical and TreatmentAspects”,
Rijeka, Croatia, InTech 2011 version “Online www.intechopen.
com Pg 327- 368.
16. Berkman J and Rifkin H. Unilateral nodular diabetic
glomerulosclerosis (Kimmelstiel-Wilson): Report of a case-
Metabolism 1973; 22: 715–722.
17. Béroniade V.C. , Lefebvre R., Falardeau P. Unilateral Nodular
Diabetic Glomerulosclerosis: Recurrence of an Experiment of
Nature. Am J Nephrol 1987;7:55–59.
18. Hans-Henrik Parving, Allan R Andersen, Ulla M Smidt, Eva
Hommel, Elisabeth R Mathiesen, Per A Svendsen Effect of
antihypertensive treatment on kidney function in diabetic
nephropathy. Brit Med J 1987; 294; 1444 – 47.
19. Lewis E. J, Hunsicker L.J, Bain R.P and Rohde RD The effect
of angiotensing converting-enzime inhibition on diabetic
nephropathy. N Engl J Med 1993;329:1456-62.
20. Hans-Henrik Parving, Hendrik Lehnert, Jens Bröchner-
Mortensen, Ramón Gomis, Steen Andersen and Peter Arner.
The effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes. N Engl J Med
2001;345:870-8).
21. Durruty P., Krause P., Pérez F., García de los Ríos M., López
G., Durruty G. Microalbuminuria en diabeticos Insulino-
dependiente: Prevención de la nefropatía diabética: Rev
Medica de Chile 1990; 118: 1319).
22. Hebert LA, Bain RP, Verme D. Remision of nephrotic range
proteinuria in type 1 diabetes. Kidney Int 1994;46:1688).
23. Parving H, Brenner B, McMurray J, de Zeeuw D , Haffner S,
Solomon S et al. “Cardiorenal End Points in a Trial of Aliskiren
for Type 2 Diabetes” N Engl J Med 2012;367:2204-13).
24. The Task Force for the management ofarterial hypertension
of the European Society ofHypertension (ESH) and of the
European Society of Cardiology (ESC). 2013 ESH/ESC
Guidelines for the management of arterial hypertension. J
Hypertension 2013; 31: 1320 – 1321.
25. James PA, Oparil S, Carter BL, Cushman W, Dennison-
Himmelfarb Ch, RN, Handler J, et al. 2014 Evidence-based
guideline for the management of high blood pressure in adults:
report from the panel members appointed to the Eighth Joint
National Committee (JNC 8). JAMA 2014;311:507-20.
26. Ninomiya T , Perkovic V, de Galan, B , Zoungas S, Pillai
A., Jardine M. Et al. Albuminuria and Kidney Function
Independently Predict Cardiovascular and Renal Outcomes in
Diabetes. J Am Soc Nephrol 20: 1813–1821, 2009.
27. Brenner B , Cooper M, de Zeeuw D, William D, Mitch W, Parving
H et als. Effects of losartan on renal and cardiovascular
outcomes In patients with type 2 diabetes and nephropathy.
N Engl J Med 2001;345:861-9.
28. The ACCORD Study Group. Effects of intensive blood-pressure
[MANEJO DE LA HIPERTENSIÓN ARTERIAL EN DIABETES MELLITUS - Dr. Emilio Roessler B.]